People only start believing the story as soon as the sector/stock starts moving up until then everything remains Uncertain, Risky & Less Rewarding. Usually Bargains are opportunity to buy but unfortunately in stock markets that’s complete opposite, Bizzare. Coming to your point for Adalimumab they have developed High Concentration Adalimumab and it’s 1 of the First company to do so, also Margins are High Double Digits with Huge runway for Growth (TAM), So don’t agree with your point, let time tell.
Posts in category Value Pickr
Shilpa Medicare -Racing away on the Oncology API highway! (14-10-2023)
Biologicals in india are not a good business. Adalimumab is a low margin business with heavy competition. This will be good if they get into Exports. But then registrations are lot more expensive.
Don’’t think if people in biologicals in India are making big money. Especially MABs
Som Distilleries and Breweries (14-10-2023)
any inputs here?
Will margins have an impact when they outsouce to other bottling agency? how does that work?
Astec Lifesciences (14-10-2023)
Amalgamation into Agrovet might happen in upcoming years. The financial strength of Astec will get averaged into Agrovet.
Investing Basics – Feel free to ask the most basic questions (14-10-2023)
Financial Shenanigans by Howard Schilit is a well-known book on accounting manipulation. At home, Dr Vijay Malik’s blog contains several ideas on how to dissect financial statements, go through the detailed company analyses of a few companies. Saurabh Mukherjee’s Diamonds in the Dust has chapters on how to detect accounting quality. Follow @BeatTheStreet10 on Twitter. Read fraud / corporate governance related threads here on ValuePIckr. There will be many other sources too but these come to mind immediately.
Venus Pipes- Pipes & Tubes (14-10-2023)
Venus Pipes seems to be very well-poised to grow from here with multiple levers of variant perception playing out:
- ~60% volume growth for FY24
- 300 bps of Margin Expansion due to backward integration and other cost savings
- Promoter buying
- Favorable Product mix change with share of premium segment (Seamless) becoming higher
- Anti- Dumping duty for imports from China further aiding the
- Shift from unorganised to organized- currently there are just 3 major organised players in this segment of the market with 30% share. The remaining 70% belongs to the unorganised.
In terms of anti-thesis:
- The valuations are no more cheap with PE of 35x for FY24 earnings, some of the growth has already baked in to the share price
- Difficult to figure out the longevity of earnings beyond FY25
Any thoughts?
Disc: Biased and Invested
Angel One: Metamorphosis into a Fintech? (Previously Angel Broking) (14-10-2023)
oh yeah!!! that skipped my mind… any input on other pointers
Laurus Labs – Can Business Transform to Next Level? (14-10-2023)
ImmunoAct: Affordable treatment at price range of 30L-40L from 3Cr- 4Cr. Not only Indians, Asians will get benefitted. more optionality. Every 5 min one is positively diagnosed with blood cancer and 70000 die a year. other than speaking economically paves way to Survival and extension of one’s Life.
John Cockerill India: A Case Study on Decarbonisation of Steel (14-10-2023)
Will try to include this when I put out an update.
John Cockerill India: A Case Study on Decarbonisation of Steel (14-10-2023)
Will try to include this when I put out an update.